Immunocellular Therapeutics Stock Net Income
| IMUC Stock | USD 0.16 0.03 23.08% |
As of the 16th of February 2026, ImmunoCellular Therapeutics retains the Downside Deviation of 30.27, market risk adjusted performance of (1.09), and Risk Adjusted Performance of 0.0949. ImmunoCellular Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
ImmunoCellular Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ImmunoCellular Therapeutics' valuation are provided below:ImmunoCellular Therapeutics does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. ImmunoCellular |
ImmunoCellular Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ImmunoCellular Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ImmunoCellular Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in ImmunoCellular Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding ImmunoCellular Therapeutics or generate 0.0% return on investment in ImmunoCellular Therapeutics over 90 days. ImmunoCellular Therapeutics is related to or competes with Hookipa Pharma, Devonian Health, and Propanc Biopharma,. Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics a... More
ImmunoCellular Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ImmunoCellular Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ImmunoCellular Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 30.27 | |||
| Information Ratio | 0.1034 | |||
| Maximum Drawdown | 223.8 | |||
| Value At Risk | (35.45) | |||
| Potential Upside | 28.57 |
ImmunoCellular Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmunoCellular Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ImmunoCellular Therapeutics' standard deviation. In reality, there are many statistical measures that can use ImmunoCellular Therapeutics historical prices to predict the future ImmunoCellular Therapeutics' volatility.| Risk Adjusted Performance | 0.0949 | |||
| Jensen Alpha | 3.76 | |||
| Total Risk Alpha | 1.05 | |||
| Sortino Ratio | 0.1159 | |||
| Treynor Ratio | (1.10) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmunoCellular Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ImmunoCellular Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0949 | |||
| Market Risk Adjusted Performance | (1.09) | |||
| Mean Deviation | 16.27 | |||
| Semi Deviation | 15.51 | |||
| Downside Deviation | 30.27 | |||
| Coefficient Of Variation | 948.29 | |||
| Standard Deviation | 33.93 | |||
| Variance | 1151.2 | |||
| Information Ratio | 0.1034 | |||
| Jensen Alpha | 3.76 | |||
| Total Risk Alpha | 1.05 | |||
| Sortino Ratio | 0.1159 | |||
| Treynor Ratio | (1.10) | |||
| Maximum Drawdown | 223.8 | |||
| Value At Risk | (35.45) | |||
| Potential Upside | 28.57 | |||
| Downside Variance | 916.16 | |||
| Semi Variance | 240.65 | |||
| Expected Short fall | (36.67) | |||
| Skewness | 3.48 | |||
| Kurtosis | 16.29 |
ImmunoCellular Therapeutics Backtested Returns
ImmunoCellular Therapeutics is out of control given 3 months investment horizon. ImmunoCellular Therapeutics holds Efficiency (Sharpe) Ratio of 0.11, which attests that the entity had a 0.11 % return per unit of risk over the last 3 months. We are able to break down and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 3.58% are justified by taking the suggested risk. Use ImmunoCellular Therapeutics Risk Adjusted Performance of 0.0949, market risk adjusted performance of (1.09), and Downside Deviation of 30.27 to evaluate company specific risk that cannot be diversified away. ImmunoCellular Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -3.26, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ImmunoCellular Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, ImmunoCellular Therapeutics is expected to outperform it. Use ImmunoCellular Therapeutics sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on ImmunoCellular Therapeutics.
Auto-correlation | 0.39 |
Below average predictability
ImmunoCellular Therapeutics has below average predictability. Overlapping area represents the amount of predictability between ImmunoCellular Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ImmunoCellular Therapeutics price movement. The serial correlation of 0.39 indicates that just about 39.0% of current ImmunoCellular Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.39 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, ImmunoCellular Therapeutics reported net income of (5.15 Million). This is 101.51% lower than that of the Biotechnology sector and 107.35% lower than that of the Health Care industry. The net income for all United States stocks is 100.9% higher than that of the company.
ImmunoCellular Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoCellular Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics of similar companies.ImmunoCellular Therapeutics is currently under evaluation in net income category among its peers.
ImmunoCellular Fundamentals
| Return On Equity | -23.12 | |||
| Return On Asset | -4.4 | |||
| Current Valuation | (1.69 M) | |||
| Shares Outstanding | 4.19 M | |||
| Shares Owned By Insiders | 94.96 % | |||
| Number Of Shares Shorted | 165.95 K | |||
| Price To Earning | 0.02 X | |||
| Price To Book | 0.35 X | |||
| EBITDA | (6.07 M) | |||
| Net Income | (5.15 M) | |||
| Cash And Equivalents | 933.15 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.78 M | |||
| Debt To Equity | 0.39 % | |||
| Current Ratio | 1.51 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (2.31 M) | |||
| Short Ratio | 4.13 X | |||
| Earnings Per Share | 28.91 X | |||
| Target Price | 5.0 | |||
| Beta | 1.03 | |||
| Market Capitalization | 2.21 M | |||
| Total Asset | 30.08 M | |||
| Retained Earnings | (74.14 M) | |||
| Working Capital | 22.29 M | |||
| Current Asset | 24.56 M | |||
| Current Liabilities | 2.27 M | |||
| Z Score | -2.8 |
About ImmunoCellular Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmunoCellular Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoCellular Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoCellular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmunoCellular Pink Sheet
ImmunoCellular Therapeutics financial ratios help investors to determine whether ImmunoCellular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmunoCellular with respect to the benefits of owning ImmunoCellular Therapeutics security.